Ocular Therapeutix, a drugs company for eye problems formerly known as I-Therapeutix, has extended its series D round by nearly $10m from a consortium including Ascension Health Ventures, the corporate venturing unit of Ascension Health hospitals group.
Ocular said that “after considering offers from several new investors, the decision was made to accommodate the strong existing investor interest by extending the prior round of financing. All existing institutional investors, including Polaris Ventures, Versant Ventures, SV Life Sciences, Sparta, and Ascension Health Ventures participated at or above their pro-rata level in the current financing.”
In February 2011, Ocular raised $14m in its D round round from a consortium led by Ascension Health Ventures, which manages $325m on behalf of 200 acute care hospitals in the US.
Ocular previously raised $15m in June 2009 from venture capital firm Polaris Venture Partners, SV Life Sciences and Versant Ventures. The B round raised $6m in March 2008 from SV and Versant and A round raised $1m.